A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia
about
Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment optionsPharmacologic treatment of schizophreniaMeta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophreniaElucidating the role of neurotensin in the pathophysiology and management of major mental disorders.Sarcosine attenuates toluene-induced motor incoordination, memory impairment, and hypothermia but not brain stimulation reward enhancement in miceClinical and biochemical study of d-serine metabolism among schizophrenia patients.PICK1 Genetic Variation and Cognitive Function in Patients with Schizophrenia.Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain.From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia.Disruption of hippocampal-prefrontal cortex activity by dopamine D2R-dependent LTD of NMDAR transmission.Psychosocial functioning in schizophrenia: are some symptoms or demographic characteristics predictors across the functioning domains?Glycine transporter type 2 (GlyT2) inhibitor ameliorates bladder overactivity and nociceptive behavior in ratsAdding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex.NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease.D-Amino-Acid Oxidase Inhibition Increases D-Serine Plasma Levels in Mouse But not in Monkey or Dog.Molecular imaging as a guide for the treatment of central nervous system disordersEffects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.The treatment of cognitive impairment in schizophrenia.Emerging drugs for schizophrenia.Overview of glutamatergic neurotransmission in the nervous system.Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.Glutamatergic transmission in schizophrenia: from basic research to clinical practiceD-serine and schizophrenia: an update.Glutamate neurocircuitry: theoretical underpinnings in schizophrenia.Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments.Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system.Targeting of NMDA receptors in new treatments for schizophrenia.Drug repurposing and emerging adjunctive treatments for schizophrenia.Sarcosine treatment for oppositional defiant disorder symptoms of attention deficit hyperactivity disorder children.Enhancing NMDA Receptor Function: Recent Progress on Allosteric Modulators.Beyond dopamine: glutamate as a target for future antipsychotics.Supplementation with D-serine prevents the onset of cognitive deficits in adult offspring after maternal immune activation.The effect of add-on memantine on global function and quality of life in schizophrenia: A randomized, double-blind, controlled, clinical trial.D-serine, a novel uremic toxin, induces senescence in human renal tubular cells via GCN2 activation.
P2860
Q22241447-69B985C5-B0B2-45A3-AD60-BFC3FF061F79Q24604457-0C129151-D974-4637-9887-EFC6DB0C2B72Q28248687-5C9B23F2-670D-4C3B-8B76-E05E8E7D206DQ30426586-453D9F5A-9DDA-4EA2-9460-1AA61CB7AB51Q30528784-1F22321C-B73C-4EBD-ADB2-38FA493E367BQ33565101-2A6CE108-F1C2-477A-AD00-B60264CA4C48Q33689579-256F4661-8F24-4E03-8A61-9530DD8A2A6EQ34230984-7EB2E0B7-AAD8-4CAD-A55A-EA56C2E74899Q34274859-ED32CBDA-71F3-4E70-9893-46577DF90679Q34330678-61ECAA3F-2BDF-4A20-887F-3C5E54B15170Q34381226-AD288258-EF22-433B-BEA1-841C083DC463Q34632695-2D6394F0-9D6B-4E4F-B1DC-15EA1656D594Q35958805-B720971D-9BB6-4EC1-ACAD-FF7761E2630FQ36055697-893E0179-DD8E-416E-BAFC-645EB290EEB3Q36140353-878460EF-8939-41AE-83F5-D8FF85C7FEBAQ36150102-DFEDCE89-5B53-42D8-8A3F-3C1935ABF092Q36247426-0F2967B1-C056-4289-9A05-063DC4C11DE3Q36310524-000EB16E-5E19-4D8B-876F-6CC53A72218EQ36799037-5A111718-20BC-4380-97C7-E81C309F0F3CQ37262953-537688FF-9666-4350-869D-9644CF7A3C08Q37662441-3946B1C5-1B94-437F-A6AF-4E0DCC0ECD67Q37813206-82D54222-CF6C-4387-8205-328E37065E03Q37874626-60DEEB04-2A75-48A4-808D-73B88896B2EFQ37926162-7694E851-2A71-4D34-A53E-D76035EA10AAQ37954123-B7884539-824C-44E1-8C26-BABD60D367E4Q37979291-8B107B29-7CE4-4230-8BCC-BD2E6D508AECQ37980657-9EBA5857-8EDF-4A4D-A2A0-29A0AE7BAFDDQ38031285-F0CB8B75-D7C1-4A10-9344-CBE126C91CF9Q38063195-722BDE3A-B6F7-46DD-8D59-ED8EED22C7FEQ38151703-19B35770-2A1C-4F35-BC2D-88B7847C5B43Q38187948-803455E7-B12C-473A-97A8-5FBFAA8E60B4Q38207021-9FF837B4-B002-4456-AF2D-60E4CDA1D8A8Q38223276-D90C3B9E-B4D6-4545-B51F-D28B8D52949FQ38417631-D217C33F-53E8-43E7-AD90-013B1854EA6BQ38839164-26F75DF8-034F-4F23-A1E3-FDCA0AAABFF3Q39121207-7A2ED611-457A-4CA3-BEF9-BE0E364FC692Q39580232-4BB32121-5AF6-48DA-BE41-F33AD3B233D8Q40448883-C2A422CE-DC88-42E7-BE5C-EA740709CFE7Q41098334-E98E37F8-47CE-48AE-A5B1-8A4A58FB30AAQ41331053-738773E9-5C92-4AFB-B452-F4BA29AA15A4
P2860
A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A randomized, double-blind, pl ...... on treatment for schizophrenia
@ast
A randomized, double-blind, pl ...... on treatment for schizophrenia
@en
A randomized, double-blind, pl ...... on treatment for schizophrenia
@nl
type
label
A randomized, double-blind, pl ...... on treatment for schizophrenia
@ast
A randomized, double-blind, pl ...... on treatment for schizophrenia
@en
A randomized, double-blind, pl ...... on treatment for schizophrenia
@nl
prefLabel
A randomized, double-blind, pl ...... on treatment for schizophrenia
@ast
A randomized, double-blind, pl ...... on treatment for schizophrenia
@en
A randomized, double-blind, pl ...... on treatment for schizophrenia
@nl
P2093
P2860
P1476
A randomized, double-blind, pl ...... on treatment for schizophrenia
@en
P2093
Ching-Hua Lin
Chun-Hui Liao
Guochuan E Tsai
Hsien-Yuan Lane
Yu-Jhen Huang
Yue-Cune Chang
P2860
P304
P356
10.1017/S1461145709990939
P407
P577
2010-05-01T00:00:00Z